^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

    Published date:
    06/21/2022
    Excerpt:
    Nivolumab or cabozantinib should be offered to patients who progressed on a VEGFR TKI alone…
    DOI:
    10.1200/JCO.22.00868
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    First-line treatment for advanced ccRCC...Cabozantinib [II, A] is also an alternative in IMDC intermediate- and poor-risk disease for those patients that cannot receive first-line PD-1 inhibitor-based therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/03/2021
    Excerpt:
    First-line therapy for clear cell histology: Other recommended regimens…Cabozantinib (category 2B).